UPDATE: Deutsche Bank Downgrades Amedisys Following Q3 Miss

In a report published Wednesday, Deutsche Bank analyst Darren Lehrich downgraded the rating on Amedisys AMED from Hold to Sell, and lowered the price target from $11.00 to $8.00. In the report, Deutsche Bank noted, “AMED's Q3 miss provides further evidence that the co's operations are unstable, and its margin structure is on even shakier ground heading into re-basing. While the tentative DOJ settlement provides resolution on legacy issues, we believe the size of the fine ($150M), combined with the co's amended credit facility and a lower EBITDA run-rate severely limit AMED's flexibility going forward.” Amedisys closed on Tuesday at $14.32.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesAnalyst RatingsDarren LehrichDeutsche Bank
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!